[
    [
        {
            "time": "",
            "orginal_text": "泛生子宣布与复星医药签订Seq-MRD?独家商业化合作协议",
            "features": {
                "keywords": [
                    "泛生子",
                    "复星医药",
                    "Seq-MRD",
                    "独家合作",
                    "商业化协议"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "泛生子宣布与复星医药签订Seq-MRD?独家商业化合作协议",
            "scores": {
                "News_content": "泛生子宣布与复星医药签订Seq-MRD?独家商业化合作协议",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "复星医药与泛生子达成独家合作 推动血液肿瘤监测服务国内落地",
            "features": {
                "keywords": [
                    "复星医药",
                    "泛生子",
                    "独家合作",
                    "血液肿瘤",
                    "监测服务",
                    "国内落地"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "复星医药与泛生子达成独家合作 推动血液肿瘤监测服务国内落地",
            "scores": {
                "News_content": "复星医药与泛生子达成独家合作 推动血液肿瘤监测服务国内落地",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "泛生子(GTH.US)与复星医药(02196.HK)达成独家合作，携手推动血液肿瘤监测服务在华落地",
            "features": {
                "keywords": [
                    "泛生子",
                    "GTH.US",
                    "复星医药",
                    "02196.HK",
                    "独家合作",
                    "血液肿瘤",
                    "监测服务",
                    "在华落地"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "original_text": "泛生子(GTH.US)与复星医药(02196.HK)达成独家合作，携手推动血液肿瘤监测服务在华落地",
            "scores": {
                "News_content": "泛生子(GTH.US)与复星医药(02196.HK)达成独家合作，携手推动血液肿瘤监测服务在华落地",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "",
            "orginal_text": "舍得酒业：辟谣老酒利空后发布三季报，多空厮杀谁能笑到最后？",
            "features": {
                "keywords": [
                    "舍得酒业",
                    "辟谣",
                    "老酒利空",
                    "三季报",
                    "多空厮杀"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "白酒",
                    "消费品"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "舍得酒业：辟谣老酒利空后发布三季报，多空厮杀谁能笑到最后？",
            "scores": {
                "News_content": "舍得酒业：辟谣老酒利空后发布三季报，多空厮杀谁能笑到最后？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "国泰君安：新冠疫苗进入业绩兑现期，港股部分标的将受益",
            "features": {
                "keywords": [
                    "国泰君安",
                    "新冠疫苗",
                    "业绩兑现期",
                    "港股",
                    "标的受益"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技",
                    "港股"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "国泰君安：新冠疫苗进入业绩兑现期，港股部分标的将受益",
            "scores": {
                "News_content": "国泰君安：新冠疫苗进入业绩兑现期，港股部分标的将受益",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "每日理财观察：证监会正评估完善试点注册制各项安排",
            "features": {
                "keywords": [
                    "证监会",
                    "试点注册制",
                    "评估完善",
                    "各项安排"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "政策",
                    "资本市场"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "每日理财观察：证监会正评估完善试点注册制各项安排",
            "scores": {
                "News_content": "每日理财观察：证监会正评估完善试点注册制各项安排",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]